Behold.ai Global Technologies Limited marks the next chapter for one of the most clinically validated AI platforms in medical imaging. Following the acquisition of the full intellectual property and assets of Behold.ai Technologies Limited, we are relaunching the proven red dot® AI platform—starting with its powerful lung cancer detection capabilities.
red dot® has already demonstrated exceptional real-world performance, analyzing over 32,000 patients with zero missed lung cancers across three years, and is both FDA-cleared and CE-marked.
Now under new leadership, Behold.ai Global is reactivating this groundbreaking technology, rebuilding the expert team behind it, and expanding our product pipeline. Our focus is on delivering accurate, efficient, and regulatory-compliant AI tools that support radiologists and improve patient outcomes worldwide.
This is more than a relaunch—it’s a reinvention. We’re looking ahead to new clinical applications, new markets, and a new era of AI in diagnostic imaging.
Innovative solutions are needed to improve patient outcomes through faster diagnosis and earlier treatment.
The problem
Healthcare systems globally are systematically challenged
Increasing lung cancer deaths
2m
deaths globally
#1
Single largest cause of cancer-related deaths globally
Rising outsourcing costs
Government spending on healthcare globally
is at an all time high
Rapid rises in outsourcing costs
(280% increase in volume in the last 6 years)
Record levels of patient backlog
6m+
backlog in the UK alone rising to 12m+
Radiologist shortage
Global shortage of trained radiologists
Key milestones
We are first to have regulatory approval in the UK and EU
CQC Registered
First and only AI company to be registered by the CQC
FDA Cleared
FDA 510(k) clearance for triage of Pneumothorax
CE Marking
First company with CE marking for diagnosis of CXRs
Commercial partnerships
Phase 4 AI Award Winner for national rollout
For our lung cancer detection platform and autonomous rule out on CXR being deployed across 10 UK NHS sites
Approved for NHS Share Business Framework
FDA 510(k) clearance for triage of Pneumothorax
US Distribution Partnership
Merative has over 23% of the PACS imaging systems market share in US.
India Distribution Partnership
Apollo Hospital Group is the largest hospital group in SE Asia with over 71 hospital locations across India.
Interested in talking to us about AI?
Get in touch to learn more about how red dot® can make a difference to your patients and your organisation.
Regulated and recognised
